Eden Research Plc · LSE:EDEN
Eden Research — Shareholder Meeting (June 2022)
35 slides from Eden Research's shareholder meeting presentation, Jun 29, 2022
Slide 1: Eden Research plc 2022 Annual General Meeting
Eden Research plc 2022 Annual General Meeting 29th June 2022 London, United Kingdom
Slide 2: Eden Research plc is an AIM-quoted company
Eden Research plc is an AIM-quoted company focused on sustainable biopesticides and plastic-free encapsulation technology for use in the global crop protection, animal health and consumer products industries.
Slide 3: About us and key statistics
About us Key statistics Eden is the only UK quoted Fundraise of £10.4m (AIM: EDEN) company (gross) in March 2020 to: focused on biopesticides for sustainable agriculture • Register and commercialise insecticide products 18 • Develop use of our Countries have granted • Intellectual property and exper
Slide 4: Industry applications
Industry applications We work globally through multi-national and local partnerships to develop and launch solutions for challenges facing three key industries. Consumer products Crop protection Animal health Head-lice treatment Foliar disease & Shampoos/Conditioners Deodorants insect control Skin d
Slide 5: Significant Market Potential
Significant Market Potential $11bn Crop protection products formulated with Sustaine® and Eden’s active ingredients can help address many of these issues: The global biopesticides market is projected to be worth more than $11 billion by 2027 Consumer concerns 15% per annum over food safety The biope
Slide 6: The Drive Towards Sustainable Agriculture
The Drive Towards Sustainable Agriculture Farming practices which Embracing farming maintain yields while increasing practices that mimic natural benefits for the environment ecological processes Eden formulations are A reflection of society’s A win-win for farmers and well suited for a wide increas
Slide 7: 2021 Overview and Results
— — = — Lo | eel THE NATURAL SOLUTION 2021 Overview and Results
Slide 8: 2021 Overview Portfolio Expansion
2021 Overview Portfolio Expansion The expansion of Eden’s existing portfolio into seed treatments and insecticides aligns perfectly with our values of focusing on sustainable solutions for agricultural challenges. Modest product sales Eden signed an exclusive Diversification and Eden was the first E
Slide 9: 2021 Results
2021 Results Overview 2021 2020 Notes • Product sales increased 4% by volume Revenue £1.2m £1.4m and 6% on a constant currency basis. Product sales revenue £1.1m £1.1m • Sales of Mevalone continued to be negatively impacted for use on wine Other revenue £0.1m £0.3m grapes, due to a decline in demand
Slide 10: Mevalone Eden sales to distributors 2018-2021
Mevalone® Eden sales to distributors 2018 - 2021 As has been previously communicated to shareholders, post-season sales in Eden Mevalone sales (L) 2019 were strong, with good ex-distributor sales growth expected in 2020, following ex-distributor sales growth of 35% seen in 2019. The global COVID-19
Slide 11: Mevalone Distributor sales 2018-2021
Mevalone® Distributor sales 2018 - 2021 Sales of Mevalone made by our distribution partners in the same period Ex-distributor Mevalone sales (L) reflect a positive overall trend driven by the addition of new territories (e.g., Australia) and label expansions (e.g., Spain). Despite a small decrease i
Slide 12: A Strong Team
A Strong Team Lykele van der Robin Cridland Sean Smith Alex Abrey Broek Non-Executive CEO CFO Chairman Director Sean Smith CEO Alex Abrey CFO Laboratories and Commercial Head of Product Director of Head of R&D Facilities Manager Director Management Regulatory Affairs Consultant Development Team Lead
Slide 13: Innovation Capacity
Innovation Capacity Development of Laboratories are Progress is being in-house R&D – now GLP-ready and made on the potential reduces dependency operating to this benefits of the on 3rd parties, standard adding second-generation CROs, etc. In-house capabilities credibility and Costs partially offset
Slide 14: Strategy and Investment Case
Strategy and Investment Case
Slide 15: Our Strategy
Our Strategy Research, Business line Commercial Strengthening and development diversification growth growing the team and operations • Pursuit of opportunities in seed • Supply chain optimisation • Regulatory clearance in new • Added capacity in R&D, including treatments • Expansion of in-house scre
Slide 16: Commercial Footprint
Commercial Footprint Our presence in Europe grew in 2020-21 through new authorisations for both Cedroz™ and Mevalone®, and we anticipate further approvals in Europe and further abroad in 2022. There was a total of six new approvals in 2021. Our US EPA approval for the Commercial sale of Mevalone® an
Slide 17: Mevalone Regulatory Progress 2019-2021
Mevalone® Regulatory Progress 2019 - 2021 Since 2019 31 5x Increase in disease targets 12 13 10 10 8 5x 2 6 4 Increase in crop authorisations 2019 2020 2021 30% No. countries authorised Increase in country No. of disease targets authorisations No. of Crops
Slide 18: Regulatory position
Regulatory position EFSA (EU) Organic (EU) • Application for the renewal of Eden’s three • All three of Eden’s active ingredients have active ingredients (eugenol, geraniol and thymol) been approved as inputs for organic has been submitted to EFSA for its review. agriculture in the EU. • The renewed
Slide 19: Organic Growth: Current Products
Organic Growth: Current Products
Slide 20: Our product focus
Our product Our focus is on developing products based on sustainable chemistries to protect crops from pests focus and disease, with equal or better performance when compared with conventional pesticides. FUNGICIDES NEMATICIDES INSECTICIDES SEED TREATMENTS Botrytis, powdery Root knot Mites and Multi
Slide 21: Product Characteristics
Product Characteristics Enabling sustained Tackling Solvent-free, stable Protecting plants Polymer-free ‘Residue Low or no delivery, increasing resistance formulations with from potentially formulation free’ pre-harvest intervals residual efficacy and build-up high loadings of damaging chemicals tec
Slide 22: Positive Outlook for Organic Growth
Positive Outlook for Organic Growth How organic growth will be achieved The team at Eden now has the necessary capabilities to formulate, develop, test (up to pot plant level) and register products that it has created. Label extensions and country approvals of Mevalone and Cedroz continue to increas
Slide 23: Mevalone Biofungicide
Mevalone® Biofungicide Background Current status Mevalone is a foliar biofungicide which was Approved in Southern EU on a wide range of targets and crops developed initially to target botrytis on grapes. Approved in Kenya and Australia Since its launch in the EU in 2016, the label for Approval in th
Slide 24: Cedroz Bio-nematicide
Cedroz™ Bio-nematicide Background Current status Cedroz is a bio-nematicide targeting Approved in Southern and Central EU on a wide range root-knot nematodes in high value crops. of high-value crops A development and commercialisation Approval in the US expected in 2022 agreement was signed with Eas
Slide 25: Downy mildew: Filling a gap in the market
Downy mildew Filling a gap in the market Background Current status Due to the recent restriction of a number Second year regulatory field trials are currently underway of key downy mildew products, there is a with results expected in Q3, 2022. strong need for replacement products. There are currentl
Slide 26: Significant additional growth opportunities
Significant additional growth opportunities Cannabis Other Eden has been approached by a new potential partner Evaluations in additional to see if Mevalone, or any other Eden formulation, areas of significant commercial would be suitable to target the cannabis market in the potential include black U
Slide 27: Return to product sales growth
Return to product sales growth Eden product sales (€) Current status 2,000,000 1,800,000 The table shows forecast growth in Eden’s 1,600,000 product sales for Mevalone and Cedroz in 2022 of around 28%, per Cenkos’ forecast*. 1,400,000 1,200,000 There are additional opportunities for further 1,000,00
Slide 28: Organic Growth: New Products
Organic Growth: New Products
Slide 29: Seed Treatments
Seed Treatments Key information What are Seed Treatments? Physical, biological or chemical agents applied SEED SEED SEED to seeds to provide protection and help improve overall crop performance DRESSING COATING PELLETING Multiple functions: supporting greater uniformity of seed germination, plant he
Slide 30: Seed Treatments – Corteva: On the path to commercialisation
Seed Treatments – Corteva On the path to commercialisation Background Current status Two incumbent ingredients used in Semi-field studies have shown good efficacy Corteva’s seed treatment products have been, or will shortly be, banned in key Field trials, undertaken by both parties, showed efficacy
Slide 31: Insecticide: Significant opportunities for effective, new products
Insecticide Significant opportunities for effective, new products Background Current status Due to a ban on numerous insecticides, Initial data received from the field trials which are currently such as neonicotinoids, there is a large underway shows good efficacy, consistent with that in 2021 oppor
Slide 32: Sustaine projects: Addressing the rising microplastics issue
Sustaine® projects Addressing the rising microplastics issue Background Current status In addition to using microencapsulation Field trials underway with multiple industry partners. system, Sustaine, in our in-house developed products, such as Mevalone and Cedroz, Decisions regarding future evaluati
Slide 33: Outlook
Outlook Strong balance sheet and a return to year over year growth despite challenging conditions Moving forward with our new products, including insecticide products, seed treatments and optimised fungicides Additional regulatory approvals expected in 2022 with commercial impact this year and beyon
Slide 34: Summary Portfolio Expansion
Summary Portfolio Expansion The expansion of Eden’s existing portfolio into seed treatments and insecticides aligns perfectly with our values of focusing on sustainable solutions for agricultural challenges. Eden was the first company in Eden’s commercial partner, Eden signed an exclusive Eden’s com
Slide 35: Thank you
D N Lo | eel THE NATURAL SOLUTION Thank you